Paul,
>Would it be fair to say that HA's have not been so worried about their 50%
>under national average practices as the 50% over ones?
Not entirely fair. IME there is concern about practices which seem to
underspend in certain areas.
>I have heard the steroid inhaler % quoted before as a quality marker, but
>not the glibenclamide one.
Both are actually cost more.
>So how are PCG's going to justify pressurising
>the high cost practices when the art of assessing
>quality prescribing is so under developed?
Mark Campbell who sometimes appears on the list is the one who
is developing/has developed prescribing indicators.
I would suggest that employing the likes of me to work with
practices could help to achieve a more cost efficient drugs bill.
Regards
Jeff Green
==================================================
Community Locum and Prescribing Support Pharmacist
[log in to unmask]
==================================================
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|